Advertisement

Drugs & Therapy Perspectives

, Volume 7, Issue 9, pp 10–13 | Cite as

Guidelines can reduce the risk of clozapine-induced agranulocytosis

Drug Reactions and Interactions
  • 6 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mendelowitz AJ, Gerson SL, Alvir JMaJ, et al. Clozapine-induced agranulocytosis. Risk factors, monitoring and management. CNS Drugs 1995; 4(6): 412–21Google Scholar
  2. 2.
    Balon R, Berchov R. Hematological side effects of psychotropic drugs. Psychosomatics 1986; 27: 119–27PubMedCrossRefGoogle Scholar
  3. 3.
    Jalenques I. Drug-resistant schizophrenia. Treatment options. CNS Drugs 1996; 5(1): 8–23Google Scholar
  4. 4.
    Antipsychotic selection depends on individual response and tolerability. Drug Ther Perspect 19 Jul 1993; 2(1): 8–11CrossRefGoogle Scholar
  5. 5.
    Clozapine: indications are defined by clinical not economic criteria. Drug Ther Perspect 22 Nov 1993; 2(10): 5–7CrossRefGoogle Scholar
  6. 6.
    Alvir JMaJ, Lieberman JA, Safferman AZ. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7PubMedCrossRefGoogle Scholar
  7. 7.
    Alvir JMaJ, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994; 55 (9 Suppl. b): 137–8Google Scholar
  8. 8.
    Alvir JMaJ, Lieberman JA, Safferman AZ. Do white-cell count spikes predict agranulocytosis in clozapine recipients. Psychopharmacol Bull 1995; 31: 311–4PubMedGoogle Scholar
  9. 9.
    Lieberman JA, Yunis J, Egea E, et al. HLA-B38, DR4, DQW3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47: 945–8PubMedCrossRefGoogle Scholar
  10. 10.
    Honigfeld G. Effects of the clozapine national registry system on the incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47: 52–56PubMedGoogle Scholar
  11. 11.
    Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 1994; 55 (9 Suppl. b): 139–42Google Scholar
  12. 12.
    Gerson SL. Clozapine: deciphering the risks [editorial]. N Engl J Med 1993: 204–5Google Scholar
  13. 13.
    Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 1991; 5: 21–33Google Scholar
  14. 14.
    Safferman AZ, Lieberman JA, Alvir JMaJ, et al. Rechallenge in clozapine-induced agranulocytosis [letter]. Lancet 1992; 340: 1097Google Scholar

Copyright information

© Adis lnternational Limited 1996

Personalised recommendations